7 completed, 3 recruiting, 1 active not recruiting, 1 withdrawn. 9 Phase 2, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 5, Recruiting 3, Withdrawn 1 |
| Not applicable | 2 | Active not recruiting 1, Completed 1 |
Follow Uterine Leiomyosarcoma: new trials by email Literature Review of Uterine Leiomyosarcoma trials Research Report on Uterine Leiomyosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ph 2 Elacestrant in ER Positive Uterine Sarcomas Elacestrant - Uterine Sarcoma, Uterine Leiomyosarcoma | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 30 | 2026-03-25 | 2026-05-22 |
| Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS Trabectedin, Doxorubicin Hydrochloride - Uterine Leiomyosarcoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 48 | 2025-10-02 | 2026-10-13 |
| Letrozole in Uterine Leiomyosarcoma Letrozole - Uterine Leiomyosarcoma | Phase 2 | Recruiting | GOG Foundation | 40 | 2024-07-17 | 2026-07-30 |
| Comparison Between Laparoendoscopic Single-site Surgery and Multi-port Laparoscopy in Treating Uterine Fibroids TU-LESS, MPLS - Uterine Fibroid, Uterine Sarcoma | Not applicable | Active not recruiting | West China Second University Hospital | 5000 | 2023-06-24 | 2024-02-06 |
| CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma Gemcitabine, Dacarbazine, Cytoreductive Surgery - LMS - Leiomyosarcoma, Uterine Leiomyosarcoma | Phase 2 | Completed | Stanford University | 17 | 2021-01-28 | 2026-06-25 |
| Combined CRS With HIPEC in Women With Inadvertently Morcellated uLMS CRS-HIPEC - Uterine Leiomyosarcoma | Completed | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 19 | 2016-01-01 | 2024-11-07 | |
| Pazopanib for Treating Uterine Leiomyosarcoma Pazopanib - Uterine Leiomyosarcoma | Phase 2 | Withdrawn | Gynecologic Oncology Group | 2015-03-01 | 2015-11-18 | |
| AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma saracatinib - Adult Fibrosarcoma, Adult Leiomyosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2008-02-01 | 2018-06-29 |
| Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus sunitinib malate - Recurrent Uterine Sarcoma, Uterine Leiomyosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 44 | 2006-10-01 | 2019-07-23 |
| Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma ziv-aflibercept - Fallopian Tube Cancer, Female Reproductive Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 63 | 2006-09-01 | 2015-12-07 |
| Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma sorafenib tosylate - Adult Angiosarcoma, Adult Epithelioid Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 147 | 2005-09-01 | 2014-05-23 |
| Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus Docetaxel plus Gemcitabine - Uterine Leiomyosarcoma, Uterine Cancer | Not applicable | Completed | Memorial Sloan Kettering Cancer Center | 25 | 2001-08-01 | 2015-12-22 |
Histiocytoma, Malignant Fibrous (2) · Leiomyosarcoma (2) · Sarcoma (2) · Sarcoma, Endometrial Stromal (2) · Adenosarcoma of the uterus (1) · Carcinoma, Ovarian Epithelial (1) · Dermatofibrosarcoma (1) · Fallopian Tube Neoplasms (1) · Fibrosarcoma (1) · Hemangiosarcoma (1) · Leiomyoma (1) · Liposarcoma (1) · Neurofibrosarcoma (1) · Perivascular Epithelioid Cell Neoplasms (1) · Rhabdomyosarcoma (1)
Neoplasms (6) · Neoplasms by Histologic Type (5) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Genital Diseases (4) · Genital Diseases, Female (4) · Genital Neoplasms, Female (4) · Neoplasms, Connective and Soft Tissue (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Neoplasms, Muscle Tissue (3) · Uterine Diseases (3) · Endometrial Neoplasms (2) · Endometrial Stromal Tumors (2) · Histiocytoma (2)
Gemcitabine (2) · Cytoreduction Surgical Procedures (1) · Dacarbazine (1) · Docetaxel (1) · Doxorubicin (1) · Gadolinium (1) · Letrozole (1) · Magnetic Resonance Spectroscopy (1) · RAD1901 (1) · Sorafenib (1) · Sunitinib (1) · Trabectedin (1) · aflibercept (1) · elacestrant (1) · pazopanib (1)
National Cancer Institute (NCI) (4) · Dana-Farber Cancer Institute (1) · GOG Foundation (1) · Gynecologic Oncology Group (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Stanford University (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · West China Second University Hospital (1)
United States (9) · Canada (2) · China (2)
Martee Hensley, MD (2) · Amit Oza (1) · Bradley Corr, MD (1) · Elise Nassif Haddad, MD (1) · Kristen N Ganjoo, MD (1) · Margaret von Mehren (1) · Martee Hensley (1) · Robert Maki (1) · Suzanne George, MD (1)
PMID 25051495, PMID 29078975, PMID 36933684, PMID 37093509
N01CM62201 (2), N01CM62203 (2), N01CM62206 (1), N01CM62209 (1), P30CA008748 (1), U10CA027469 (1)